Clinical trial

Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients

NCT05184049

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Epalrestat,Mecobalamin Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Mecobalamin Normalized identity: mecobalaminView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-01-01

PhasePHASE4

Conditions

Diabetesverified · MONDO: diabetes mellitus

Interventions

Epalrestat,MecobalaminDRUG

MecobalaminDRUG · verified · RxNorm: mecobalamin

Sponsors & collaborators

Xiangya Hospital of Central South Universitylead sponsor

Mapped research locations

ChangshaHunan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05184049 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.